Ocular Inserts Market Size, Share and Global Trend By Product Type (Insoluble Inserts, Soluble Inserts), By End User (Hospital, Speciality Clinics, Ambulatory Surgical Centers, Others), and Regional Forecast, 2024-2032

The eye is a very delicate and essential part of the human body. The global number of eye diseases are growing at a significant rate. According to the National Eye Institute, in 2014, almost 2.1 million people in the U.S. have advanced age-related muscular degeneration (AMD), which is projected to increase to 3.7 million by the year 2030. This also raises needs to develop ocular drug delivery methods for improved and effective results.

Ocular inserts are prominently used in ocular drug delivery for the treatment of eye problems such as dry eyes, glaucoma, decreased corneal sensitivity, burning eyes, and others. Ocular inserts are thin, sterile, multi-layered, drug-impregnated, semisolid or solid consistency devices which are placed into the conjunctival sac of the eye, whose size and shape are designed specifically for the ophthalmic application. The ocular inserts are inserted into the lachrymal canaliculus region of the eyelid. Many developments are seen in the global ocular inserts market. In December 2018, Ocular Therapeutix, Inc., one of the prominent players in eye care market, received FDA approval for their ocular insert, ‘DEXTENZA,’ for intracanalicular use in the treatment of pain associated with post-ophthalmic surgery, which is expected to accelerate the global ocular inserts market.

The growth in global ocular inserts market is mainly driven by the increasing eye care demand and favourable health reimbursement. The increased use of ocular inserts for drug delivery is one of the major drivers which is projected to favour the growth in global ocular inserts market.

However, the lack of skilled eye surgeons in under developed countries and lack of awareness regarding ocular inserts are the major restraining factors for growth in the global ocular inserts market.

Key Players Covered

Some of the major companies that are present in the global ocular inserts market are Novartis AG, Bausch & Lomb Incorporated, Ocular Therapeutix, Inc., EyeGate, etc.

SEGMENTATION

The hospital segment is expected to dominate the global ocular inserts market in terms of revenue during the forecast period due to the increasing number of eye surgeries. According to the American Academy of Ophthalmology, 2 million cataract surgeries are done each year in the U.S., which implies a growth in the ocular inserts market, as ocular inserts are also used for pain relief after surgery.

Key Insights

• Prevalence of eye diseases for key countries


• The regulatory scenario for key countries


• Pricing analysis


• New product launch


• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

In North America, the ocular inserts market is projected to grow in the forecast period, due to the increase in the prevalence of eye disease and advancements in ocular drug delivery techniques. According to National Eye Institute, in 2014, 2.7 million people in the U.S. were suffering from glaucoma, that is estimated to reach up to 4.3 million by 2030, which will further boost the ocular inserts market in this region. In Europe and the Asia Pacific, the ocular inserts market is estimated to expand during the projected period due to the increased government efforts for setting up tertiary eye institutes.

Key Industry Developments

• In January 2019, Ocular Therapeutix, Inc. announced the submission of supplement NDA to the USFDA for DEXTENZA, to expand the indication of DEXTENZA for ocular inflammation post eye surgery.


• In December, 2018, Ocular Therapeutix, Inc., received FDA approval to their ocular insert, ‘DEXTENZA’, for intracanalicular use in the treatment of pain associated with post-ophthalmic surgery.


• In January 2019, Allergan plc announced the release of positive three-month clinical data on Bimatoprost SR (Sustained-Release), a biodegradable implant intended to reduce intraocular pressure in patient having ocular hypertension. 


• In August 2016, Allergan plc acquired ForSight VISION5 and undertook ForSight’s development program on peri-ocular ring for reduction of intraocular pressure.


• Ocular Therapeutix, Inc., is conducting clinical study on OTX-TP, an insert for delivering travoprost to the ocular surface.